Isolated Hepatic Perfusion With Melphalan in Treating Patients With Primary Unresectable Liver Cancer or Liver Metastases
Status:
Completed
Trial end date:
2006-01-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die. Giving drugs in different ways may kill more tumor cells.
PURPOSE: This phase II trial is studying how well isolated hepatic perfusion with melphalan
works in treating patients with primary unresectable liver cancer or liver metastases.
Phase:
Phase 2
Details
Lead Sponsor:
National Institutes of Health Clinical Center (CC)